|Bid||0.8250 x 800|
|Ask||0.8298 x 900|
|Day's Range||0.8140 - 0.8800|
|52 Week Range||0.3300 - 1.3800|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.
Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness; Vivus soared on potential to beat weight-loss drugs with significant adverse effects Bellus ...
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
The Campbell, California-based company said it had a loss of 10 cents per share. The biopharmaceutical company posted revenue of $11.9 million in the period. In the final minutes of trading on Tuesday, ...
Company provides business update on PANCREAZE ® acquisition, new Athyrium debt line and new management. Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., May 08, 2018-- VIVUS, Inc., ...
Pursuant to Rule 14a‑8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders may present proper proposals for inclusion in the 2018 Proxy Statement and for consideration at the Company’s 2018 Annual Meeting. To be eligible for inclusion in the 2018 Proxy Statement, a proposal must be received by the Company no later than May 21, 2018 and must otherwise comply with Rule 14a‑8. In addition, under the Company’s Amended and Restated Bylaws, as further amended, in order to nominate a director or bring any other business before the stockholders at the 2018 Annual Meeting that will not be included in the 2018 Proxy Statement, the proposal must be received by the Company’s Corporate Secretary on or between May 10, 2018 and June 9, 2018.
NEW YORK, NY / ACCESSWIRE / May 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on VIVUS, Inc. (VVUS) is a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health. VIVUS has announced new management members and new initiatives over the past few trading days. On April 30, 2018 VVUS announced the addition of three executives to the Company's senior leadership team.
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on VIVUS, Inc. (NASDAQ: VVUS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VVUS as the Company's latest news hit the wire. On May 01, 2018, the Company announced that it has inked an agreement to acquire all of the product rights for Janssen Pharmaceuticals, Inc.'s PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada, for approximately $135 million.
NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Positive developments sent shares of both Avinger and VIVUS higher on Tuesday. Avinger announced that its next generationPantheris Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross International Symposium 2018. VIVUS announced that it has entered into a definitive agreement for the acquisition of PANCREAZE.
CAMPBELL, Calif., May 01, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product rights for PANCREAZE ® Delayed-Release ...
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company and Athyrium Capital Management L.P. (“Athyrium”), a specialized asset management company focused on investment opportunities in the global healthcare sector, today announced an agreement to restructure a portion of VIVUS’ corporate debt while raising new funds through the issuance of debt securities to investment funds managed by Athyrium.
VIVUS,Inc. , a biopharmaceutical company, today announced the addition of three executives to the Company's senior leadership team. John Amos has joined as the Company's new Chief Executive Officer and ...
In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.
VIVUS, Inc. today announced that it will report financial results and provide a business update for the first quarter of 2018 after the market close on Tuesday, May 8, 2018. The company will host a conference ...
On a per-share basis, the Campbell, California-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $11.9 million in the period. For the year, the company reported ...
VIVUS,Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46, ...
VIVUS, Inc. today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief executive officer and a member of the board of directors effective December ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)